Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

Background: Several studies have investigated the role of off-label non-vitamin K antagonist
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Background Although several meta‐analyses have examined the effects of off‐label
underdosing of nonvitamin K antagonist oral anticoagulants (NOACs) compared with their …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Background Dose adjustment of non‐vitamin K antagonist oral anticoagulants (NOAC s) is
indicated in some patients with atrial fibrillation (AF), based on selected patient factors or …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred class
of medications for prevention of stroke and systemic embolism in patients with atrial …

ABSTRACT Introduction: Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) are at
least as effective as vitamin K antagonists (VKAs) reducing thromboembolism and mortality …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) do not require
frequent laboratory monitoring, each compound requires dose adjustments on the basis of …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …